Tumoral MET/HGF expression and MET gene amplification in patients with ALK 2p23 fusion driven lung cancer.

11091 Background: MET receptor and its ligand HGF are both promising targets in non-small cell lung cancer (NSCLC) therapy. Crizotinib, a recently approved ALK inhibitor for NSCLC harboring oncogen...